ALLO vs RF
Allogene Therapeutics Inc (ALLO) versus RF (RF) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
RF (RF) common stock.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
RF does not have a complete income-statement cache yet.
ALLO currently screens at market cap $258.1M. RF currently screens at market cap $0.
Not investment advice. Open the ALLO and RF stock pages for the full models.
Not investment advice.